STEMI patients without standard modifiable CV risk factors face higher 30-day mortality compared with those with at least 1 risk factor.

LONDON — There appears to be no advantage for continuing anticoagulation treatment after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI), according to ...

Coronary no-reflow phenomenon (NRP), a common adverse complication in patients with ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI), is ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Coronary no-reflow phenomenon (NRP), a common adverse complication in patients with ST-segment elevation ...

A large randomized controlled trial of ischemic postconditioning in patients who had experienced the deadliest form of heart attack—ST-segment elevation myocardial infarction (STEMI)—failed to show ...

The risk of dying over the next decade for STEMI patients who survive the first 90 days after primary PCI is just a few percentage points higher than people in the general population, an observational ...

The benefit of fractional flow reserve (FFR)–guided complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains ...

Please provide your email address to receive an email when new articles are posted on . An AI-enabled ECG identified patients with STEMI, the worst kind of heart ...

The multicentre DANAMI-3-DEFER trial in Denmark (March 2011 to February 2014) found no significant clinical benefits of deferred stenting over conventional PCI with immediate stenting for patients ...

Please provide your email address to receive an email when new articles are posted on . Long-term follow-up from DANAMI-3-PRIMULTI shows reduction in events after complete revascularization vs.

Recent developments of interest in cardiovascular medicine ...